+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice



Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice



Acta Neurologica Scandinavica 133(4): 228-238



Evidence-based therapies for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consist of corticosteroids, intravenous immunglobulins (IVIg), and plasma exchange. Steroids represent the oldest treatment used historically. In countries where readily available and affordable, IVIg tends to be favored as first-line treatment. The reason for this preference, despite substantially higher costs, is the perception that IVIg is more efficacious and safer than corticosteroids. However, the unselected use of IVIg as a first-line treatment option in all cases of CIDP raises issues of cost-effectiveness in the long-term. Furthermore, serious although rare, particularly thromboembolic side effects may result from their use. Recent data from randomized trials suggest pulsed corticosteroids to have a higher potential in achieving therapy-free remission or longer remission-free periods compared with IVIg, as well as relatively low rates of serious side effects when given as pulsed intravenous infusions during short periods of time. These specific advantages suggest that pulsed steroids could in many cases be used, as the first, rather than second choice of treatment when initiating immunomodulation in CIDP, primarily in hopes of achieving a remission after the short-term use. This article reviews the evidence base for the use of corticosteroids in its various forms in CIDP and factors that may influence clinicians' choice between IVIg and pulsed steroid treatment. The issue of efficacy, relapse rate and time, and side effect profile are analyzed, and some aspects from the authors' experience are discussed in relation to the possibility of using the steroid option as first-line therapy in a large proportion of patients with CIDP.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905038

Download citation: RISBibTeXText

PMID: 26437234

DOI: 10.1111/ane.12519


Related references

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Review of Clinical Syndromes and Treatment Approaches in Clinical Practice. Journal of Clinical Neuromuscular Disease 4(4): 174-189, 2003

Schwann cells in acute inflammatory demyelinating polyradiculoneuropathy aidp and chronic inflammatory demyelinating polyradiculoneuropathy. Bollettino Societa Italiana Biologia Sperimentale 63(5): 399-406, 1987

Which criteria for research in chronic inflammatory demyelinating polyradiculoneuropathy? an analysis of current practice. Muscle & Nerve 51(6): 932-933, 2015

Clinical characteristics and course of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 37(3 SUPPL 1): 253-254, 1987

Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 37(8): 1291-1294, 1987

Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain and Behavior 6(10): E00516-E00516, 2016

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical, electrophysiological and biopsy study. Clinical Neurology and Neurosurgery 93(2): 99-106, 1991

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 110: 1617-1630, 1987

Clinical and subclinical autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle & Nerve 33(1): 78-84, 2005

Chronic inflammatory demyelinating polyradiculoneuropathy: clinical heterogeneity and therapeutic perspectives. Bulletin de L'academie Nationale de Medecine 194(4-5): 753-64; Discussion 764-5, 2011

Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies. Current Opinion in Neurology 23(3): 242-248, 2010

Multifocal demyelinating motor neuropathy: pathologic evidence of 'inflammatory demyelinating polyradiculoneuropathy'. Neurology 45(10): 1828-1832, 1995

Multifocal motor and sensory demyelinating neuropathy Pathological evidence of inflammatory demyelinating polyradiculoneuropathy. Neurology 52(6 SUPPL 2): A85-A86, April 12, 1999

Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Neurology 46(5): 1206-1212, 1996